Insulet‘s patent involves a system that provides safety constraints for insulin delivery management. The system uses sensor input to predict glucose values and adjust drug delivery accordingly to prevent under or over-delivery. It also includes mechanisms to respond to external disturbances to maintain glucose levels above a hypoglycemic threshold. GlobalData’s report on Insulet gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insulet, Wearable drug delivery devices was a key innovation area identified from patents. Insulet's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Insulin delivery system with safety constraints
A recently granted patent (Publication Number: US11883632B2) discloses a system designed to manage glucose levels in individuals using medication delivery devices. The system includes a memory for storing programming code, a communication device to interact with a glucose sensor, and a processor responsible for executing the stored code. The processor is capable of receiving glucose concentration values from the sensor, detecting decreases in these values, and adjusting medication delivery accordingly. In cases where external disturbances are identified as the cause of glucose level changes, the system can implement responses to further reduce medication delivery to maintain glucose levels above a hypoglycemic threshold.
Moreover, the system is equipped with features such as user interfaces for inputting external disturbance information, automatic detection of activities like exercise, and wearable drug delivery devices that communicate with the processor to deliver medication based on the system's responses. Safety constraints are applied by the processor to reduce insulin delivery when external disturbances pose an increased risk of hypoglycemia for the user. These constraints include adjusting target glucose values, reducing basal insulin delivery rates, and setting upper bounds on insulin delivery to ensure the user's safety during fluctuations in glucose levels caused by activities or events.
To know more about GlobalData’s detailed insights on Insulet, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
